(maybe) BETTER than a blind lottery –or MUCH m
Post# of 36563
(Total Views: 334)
Posted On: 05/19/2021 2:03:23 PM
Re: Zolis_onkel #29374
(maybe)
BETTER than a blind lottery –or MUCH more than a (complete) vaccine – with something else, other than vaccine/s
I can't tell what lottery we’re ‘playing’ in.
While it’s true that we have ‘some-thing’, this is a RACE as well (we are in competition with dozens of ‘vaccines -to-be in their way to be proven better in any aspect --so timeline 'matters' -).
Secondly, we try to outperform with our 'distinctive' platform & rationale, -- and we NEED (and deserve) results of effectiveness / safetiness exposed on trials.(again: time, money, good management, timely agreements with public and private health agents as stages go along....and unanticipated hurdles)
(after all, a successful COVID-19 vaccine would grant 'our' platform a promisory focus on so many other illnesses-disorders)
And, day-to-day financing, cash-flow, PR, CC and the like forward .....with subsidiaries showing up, so that in the long run it woudln't make much of a difference having your shares at .20 or 30. average
To recapitulate: distinctive product - timeline - management/agreements - financing -value.....and luck
(….what else?)
-for the sake of argument
sorry …..I struggle with English language/
-for the sake of illustration
https://www.gsk.com/en-gb/media/press-release...e-2-trial/
BETTER than a blind lottery –or MUCH more than a (complete) vaccine – with something else, other than vaccine/s
I can't tell what lottery we’re ‘playing’ in.
While it’s true that we have ‘some-thing’, this is a RACE as well (we are in competition with dozens of ‘vaccines -to-be in their way to be proven better in any aspect --so timeline 'matters' -).
Secondly, we try to outperform with our 'distinctive' platform & rationale, -- and we NEED (and deserve) results of effectiveness / safetiness exposed on trials.(again: time, money, good management, timely agreements with public and private health agents as stages go along....and unanticipated hurdles)
(after all, a successful COVID-19 vaccine would grant 'our' platform a promisory focus on so many other illnesses-disorders)
And, day-to-day financing, cash-flow, PR, CC and the like forward .....with subsidiaries showing up, so that in the long run it woudln't make much of a difference having your shares at .20 or 30. average
To recapitulate: distinctive product - timeline - management/agreements - financing -value.....and luck
(….what else?)
-for the sake of argument
sorry …..I struggle with English language/
-for the sake of illustration
https://www.gsk.com/en-gb/media/press-release...e-2-trial/
(1)
(0)